Labcorp (LH) said the FDA approved PGDx elio tissue complete CDx as a companion diagnostic for advanced melanoma patients with specific BRAF variants, to identify those likely to benefit from FDA-approved targeted therapies. The approval is a positive regulatory milestone that may support future test adoption, though the article provides no financial impact details.
Labcorp (LH) said the FDA approved PGDx elio tissue complete CDx as a companion diagnostic for advanced melanoma patients with specific BRAF variants, to identify those likely to benefit from FDA-approved targeted therapies. The approval is a positive regulatory milestone that may support future test adoption, though the article provides no financial impact details.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
